SOX2 and prostate cancer: For example, the report shown that loss of miR-34b is associated with progression of prostate cancer, and can accurately discriminate between benign hyperplasia and PIN lesions or infiltrating prostatic adenocarcinoma in humans, and identified the deregulation of MiR-34b/SRY-related high-mobility group box 2 (Sox2) may be as the biomarker for predicting prostate cancer progression [39].